The reason for the poorer prognosis of pseudoexfoliation syndrome glaucomas (PXSG) compared with primary open angle glaucomas (POAG) is not fully understood.
glaucoma (POAG).1-7 The reason for this is not fully understood. Pseudoexfoliation syndrome glaucoma (PXSG) is characterised by deposition of fibrillogranular pseudoexfoliative material (PXM) and dispersed pigment in and on intraocular tissues proximating the aqueous humour. The worse prognosis in PXSG could be related to increased resistance to aqueous outflow due to clogging of the trabecular meshwork by PXM, pigment, or both. How ever, pseudoexfoliation and pigment dispersion may be present in 'normal' eyes in which neither increased intra ocular pressure nor glaucoma develop. [8] [9] [10] This suggests that additional mechanisms must, at least in part, account for the difference in outcome. The more frequent need for surgical intervention1 , 4 , 5 or laser trabeculoplastyll-13 in PXSG is often a criterion used in studies which conclude with a difference in prognosis. PXSG seems to respond less satisfactorily than POAG to long-term antiglaucom atous medication, t -3,14-17 suggesting a difference in phar macokinetics in eyes with and without pseudoexfoliation. Possibly, the long-term (years) pressure reducing effects of eye medication wear off more rapidly in PXSG. Alter natively, the short-term (hours) response is less efficient in PXSG, and the cumulative effect of the daily trauma of higher pressures could more easily result in glaucomatous defects in PXSG compared with POAG.
The aim of the present study was to examine whether the short-term response to topical medication differed in the two types of glaucomas. In a cross-over study, we chose pilocarpine because it may be administered to human eyes using two markedly different pharmaco kinetic principles: pulsed drop medication and steady state continuous supply by membrane-controlled delivery (Ocusert P40, Alza).ls Since the effect of miotics increases in a systematic manner with increasing pressure,I 9-21 POAG and PXSG eyes were selected on the basis of a pro tocol allowing for good matching of pre-treatment intra ocular pressure levels.
PATIENTS AND METHODS
Out-patient Caucasian subjects were recruited, and gave their consent to participate in the study after being informed about its nature and purpose. The criteria for inclusion were as follows: (1) previous diagnosis of open angle glaucoma in one or both eyes; (2) previous treatment with pilocarpine drops; (3) responsiveness to pilocarpine; and (4) after discontinuing pilocarpine for 48 hours, a baseline intraocular pressure (pre-treatment level) �22 mmHg if pilocarpine was the only eye medication or �20 mmHg if additional medication (adrenaline or aceta zolamide, or both) was used. Patients were excluded from the study if: (1) there was a history or presence of any internal or external eye diseases; (2) any surgical eye intervention had been performed; (3) the patient used beta blocking systemic or local eye medication; and (4) the Ocusert 40 was lost during the test period and not immedi ately replaced.
Based on inclusion criteria (1) and (2) and exclusion criteria (1), (2) and (3) we recruited patients until 50 eyes with open angle glaucoma had been included. This number of eyes was reached in the first 32 patients and comprised 18 patients with bilateral and 14 patients with unilateral glaucomas. They were subjected to a thorough examination of both eyes which included a slit lamp examination after dilation of the pupils by cyclopentolate (1 %) and metaoxedrin (10%). We looked for pseudo exfoliation material (PXM) on the lens capsule, and all 50 eyes were classified as either PXM eyes or non-PXM eyes. All patients entered the study and completed the study protocol. During the experiment 2 eyes were excluded due to loss of the Ocusert without its replacement. Two eyes were not responsive to pilocarpine. Forty-eight hours after discontinuing pilocarpine 4 eyes did not reach baseline values above 22 or 20 mmHg. Since only one eye from each patient qualified for inclusion, and since comparable pre-treatment intraocular pressures in POAG and PXSG were a presupposition, an additional 12 eyes were excluded. Thus 15 patients with 15 POAG eyes and 15 patients with 15 PXSG eyes entered and completed the study.
Intraocular Pressure
Goldmann applanation tonometry was carried out for intraocular pressure (lOP) measurements. The mean pres sure of three readings was used, and the measurements were performed by alternating between the patient' s right and left eye for every reading. This was done whether or not one or both eyes had glaucoma. The mean baseline lOP values ± standard error of the mean (SE) were 25.8 ± 1.1 mmHg in POAG (n = 15) and 27.7 ± 1.1 in PSXG (n = 15); the range was 20.3-34.3 mmHg. The difference in baseline pressures (mean 1.9 mmHg) was not statistically significant (confidence interval (CI), 1.13 to 5.01; SE, 1.50; p<0.20).
Study Protocol
The study was performed as an open, comparative and
controlled study, and each patient was subjected to two experimental sessions. The patients were randomly allo cated to start either with (1) pilocarpine (2%) drop medi cation or (2) Ocusert placed in either the upper or lower cul-de-sac. Each treatment session was preceded by a 44-48 hour wash-out period without pilocarpine; an lOP reading at 9 a.m. after 24 hours of wash-out was taken as the pre-treatment baseline value. The next day (day 1) patients assigned to drops started the medication using one drop four times daily (9 a.m., 1 p.m., 5 p.m. and 9 p.m.), while the other group received the Ocusert unit at 9 a.m. In both treatment groups the lOP was measured the fol lowing morning (day 2) at 9 a.m. Thereafter, the drop treatment group was given (by us) one drop of pilocarpine, while the Ocusert group continued wearing the unit. The lOP was again measured in all patients at 11 a.m. and 1 p.m. After having completed either the drop or the Ocusert session, pilocarpine was again discontinued for another 44-48 hour wash-out period. The patients (eyes) then crossed over to the other mode of pilocarpine adminis tration, and an identical treatment session was repeated.
Statistical Analysis
Student's t-test for paired comparison was used within groups and an independent t-test for testing differences between administration forms. We defined 'normotensive pressure' as �20 mmHg, and the difference b�tween groups regarding normotension was calculated using Fisher' s exact test. Spearman's correlation coefficient was used when studying the relation between the reduced lOP and the pre-treatment level. Statistical significance was accepted at the 5% level (two-sided).
Clinical Background Data
Age ranged from 44 to 80 years (mean 64.9 years) in POAG patients (10 men, 5 women) and from 54 to 88 years (mean 73.7 years) in PXSG patients (6 men, 9 women). All patients were native Norwegians and had basically blue irides; their refractive errors ranged from -3.0 to +2.0 dioptres. The anterior chamber angle width and the trabecular pigmentation were registered by gonioscopy at 12, 3, 6 and 9 o'clock, and a mean score was given for each eye. A 4-point scale was used:22 (1) narrow angle, extreme; (2) narrow angle, moderate; (3) open angle; and (4) wide open angle. The angle width ranged from 2 to 4, averaging 3.3 for POAG eyes and 3.2 for PXSG eyes. The trabecular pigment band was graded on a 4-point scale:22 (1) slight pigmentation; (2) moderate/ slight; (3) moderate/dense; and (4) dense dark pigmenta tion band. Pigmentation ranged from 1 to 4, averaging 1.8 for POAG eyes and 2.6 for PXSG eyes. The cup/disc ratio as subjectively determined by ophthalmoscopy ranged from 0.1 to 1.0, averaging 0.7 in both POAG and PXSG eyes. Nerve fibre defects was registered by Goldmann per imetry for visual field examination using one isopter, and were observed in 5 POAG and 6 PXSG eyes. The defects ranged from a wide blind spot to loss of no more than a nasal quadrant. Adrenaline 1 % twice a day was used by 4 lOP mmHg ..
----Drops -----Ocusert P40 'eyes' with POAG and 7 eyes with PXSG, while acetazo lamide 250 mg twice daily was used by 3 POAG and 3 PXSG eyes. These medications were continued unchanged during the study. Fig. 1 gives the mean lOP ± SE of the 15 POAG and 15 PXSG eyes using pilocarpine drop medication and the Ocusert unit. The pressure reducing effect of Ocusert was greater than that of pilocarpine drops at 9 a.m. (day 2) in both types of glaucoma, (mmHg (± SE), CI): in POAG 1.7 (± 0.8),0.01 to 3.43 (p<0.05); and in PXSG 4.5 (± 1.5), 1.34 to 7.74 (p<0.01) (Fig. 1) . Furthermore, Fig. 1 shows that the 9 a.m. drop of pilo carpine on day 2 further reduced lOP to a significantly lower level in POAG (p<0.005) and PXSG (p<0.02) through 11 a.m. and 1 p.m. No differences between Ocu sert and pilocarpine drops were observed at 11 a.m. or 1 p.m. in either type of glaucoma. Table I shows that pilocarpine drops and Ocusert sig nificantly reduced the 9 a.m. (day 2) pressure in both types of glaucoma. The pressure reduction achieved with the Ocusert was no different in POAG and PXSG (7.2 mmHg and 7.1 mmHg, respectively), while the 'carry-over' pres sure lowering effect of pilocarpine drops was significantly smaller in PXSG (0.1 mmHg) than in POAG (3.0 mmHg; p<O.05) ( Table I) . Fig. 2 illustrates the percentage of eyes in which lOP was lowered to a 'normotensive' level (�20 mmHg) at 9 a.m. (day 2) in POAG and PXSG using either pilocarpine drops or Ocusert. The number of normotensive POAG eyes, using pilocarpine drops and Ocusert, was 8 of 15 The PXSG patients were somewhat older (74 years) than the POAG patients (65 years), and we sought a poss ible relation between age and mean lOP reduction. We analysed this relation from baseline to 9 a.m. on day 2, after the drop medication had been performed by the patients themselves, and at 11 a.m. on day 2 after the pilo carpine drop had been instilled by one of the authors (O.B.-H.). Including all 30 eyes, the regression lines (Pearson's) y = ax + b, where y is the reduction in lOP and x is age) were y = O.01x + 3.4 and y = 0.009x + 2.4, respectively, i.e. no relation between age and reduction in lOP was found in our patients.
RESULTS

DISCUSSION
The hypothetical rationale for the design of the present study was that PXM or abnormalities of pigment distri bution could interact with intraocular drug absorption or depot function, or inactivate pulsed drop medication ( = abnormal drug metabolism). If this explanation were valid, the worse prognosis in PXSG could be caused by complete or partial loss of pressure control in the 12 hours (9 p.m. to 9 a.m.) between drop medications in PXSG but not in POAG. This was found to be the case in the present study.
Furthermore, a continuous supply of pilocarpine to pre sumed normal pressure reducing 'receptors' could poten tially 'short-cut' the abnormal drug metabolism in PXSG. If this explanation were valid, Ocusert should be capable of pressure reduction of similar strength in both PXSG and POAG. This was also found to be the case in the study. Accordingly, the results suggest a difference in the pharmacokinetics of pilocarpine drop medication in the two types of glaucomas, affecting either absorption, depot function or inactivation of the drug. Absorption of the drug may not be the main problem since the maximum pressure reducing response was not very different in PXSG and POAG. Furthermore, the sensitivity of the pressure reducing 'receptors' may not be different in the
two types of glaucomas: a 7.2 mmHg and a 7.1 mmHg pressure reduction were obtained in POAG and PXSG, respectively, both responding to a continuous supply of pilocarpine (Ocusert unit).
The depot function of pilocarpine in intraocular tissues is well documented. The duration of the pressure reducing effect of a single drop of medication23 exceeds, by far, the time when pilocarpine is present in the aqueous.24 Send elbeck et al.25 studied the distribution of pilocarpine in dif ferent ocular tissues in rapbits using both drop medication and an Ocusert unit. They found that the depot levels in cornea, iris and sclera 3-6 hours after drop administration were approximately equal to those maintained by the Ocusert unit. This coincides with the pressure reducing effects found 2 and 4 hours after drop instillation. The Ocusert and the pilocarpine drop were equally effective in keeping the pressure low at 11 a.m. and 1 p.m., in both POAG and PXSG eyes.
Correspondingly, we feel it can be assumed that the latest pilocarpine drop (9 p.m. on day 1) in a normal four times a day regime was equally effective in both types of glaucomas through the first 4 hours of the night interval. The 'carry-over' effect through late night and early morn ing was, however, significantly smaller in PXSG, suggest ing a shorter intraocular duration of effect of the drop medication.
We may speculate why this was the case. Melanin is a specific binding site for drug absorption,26,27 and heavy ocular pigmentation somehow binds topically adminis tered drug,28-32 prolonging the duration of action of a drop medication. Possibly the pigment dispersion and loss of iris pigment, or the PXM distribution, of PXSG eyes reduce the 'normal' quantity of depots or, less likely, increase the drug elimination rate (inactivation). Experi mental studies in rabbits33,34 suggest that pilocarpine medi cation affects blood flow in the iris and ciliary processes. Perhaps blood flow in the anterior segments of POAG and PXSG eyes is basically different, or differently affected by pilocarpine, resulting in differences in depot function or inactivation of the drug, or in production of aqueous.
An insufficient response to topical medication may thus contribute to the difference in prognostic outcome, but additional factors exist. There seems to be an increased tendency in PXSG relative to POAG to develop glaucoma tous damage at any given level of IOp'35 It is not known why this is the case. Furthermore, higher lOP values are observed in PXSG compared with POAG, 1,8, 9 and this cer tainly could affect the prognosis.
In summary, the present study shows that the 'carry over' pressure reducing effect of continuous delivery of pilocarpine (Ocusert unit), through late night and early morning, is superior to drop medication in both POAG and PXSG eyes, The duration of action of pilocarpine drops is significantly shorter in PXSG eyes than in POAG eyes. In consequence only 1 of IS PXSG eyes (6.7%) was found to be 'normotensively' controlled by pilocarpine drops in the morning, compared with 8 of 15 POAG eyes (53.3%). An association between lOP peaks and progression of visual fi eld loss has been established/6 and peaks of higher lOP pressure are probably more frequent in PXSG than in POAG. Recent studies suggest that darkness and sleep37.38 and waking in the morning3 9 significantly increase lOP. The observed difference in morning lOP seems of a mag nitude large enough to suggest continuous daily trauma to nerve fibres, the cumulative effect of which is a worse long-term prognosis of PXSG.
